On June 22, Axinn partners Chad Landmon and Stacie Ropka will participate in ACI’s 12th Annual Summit on Biosimilars & Innovator Biologics virtual conference. Chad Landmon will speak on a panel entitled, "Skinny Labeling Post-GSK v. Teva: How the Decision Will Inform Biosimilar Carve-Outs." Stacie Ropka will speak on a panel entitled, "Advocating for Diversity in IP: Practical Ideas for Implementing Change."
Chad's panel will outline the implications of the Federal Circuit decision striking down labeling carve-outs. Stacie’s panel will identify best practices for evaluating your outside firm’s efforts in promoting diversity.
Click here for more information, including how to register.